For the Inventor, By the Inventor

Enter assignee name

Gyeonggi-do, South Korea

Crystalgenomics, Inc.

USPTO Granted Patents = 10

CIPO Patents = 2

EPO Patents = 6

Forward Citations = 29

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Joong Myung Cho (9 out of 13 patents)

Seonggu Ro (6 out of 6 patents)

Yong Rae Hong (3 out of 3 patents)

4. Jeong Eun Na (3 out of 6 patents)

5. Im Sook Min (3 out of 3 patents)

6. Hyun Ju Cha (3 out of 3 patents)

7. Sool Ki Kwon (3 out of 3 patents)

8. Dongkyu Shin (2 out of 7 patents)

9. Seong Gu Ro (2 out of 7 patents)

10. Jae Pyoung Cho (2 out of 2 patents)

11. Young Lan Hyun (2 out of 2 patents)

12. Young Ho Jeon (1 out of 2 patents)

13. Jae-yeon Park (1 out of 3 patents)

14. Takayuki Irie (1 out of 6 patents)

15. Masaaki Sawa (1 out of 18 patents)

10 patents: Sort by Forward Citations

1. 11655207 - Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same (2023-05-23),

2. 11602517 - Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain (2023-03-14),

3. 11230539 - 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same (2022-01-25),

4. 10604508 - 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same (2020-03-31),

5. 10413520 - Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability (2019-09-17),

6. 9758508 - 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same (2017-09-12),

7. 8119812 - Thiazolidinone derivative (2012-02-21),

8. 8053435 - Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same (2011-11-08),

9. 7973060 - Fab I inhibitor and process for preparing same (2011-07-05),

10. 7179832 - Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof (2007-02-20),

Crystalgenomics, Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of various diseases. The company utilizes its expertise in crystallography and computational chemistry to identify small molecule drug candidates with high efficacy and safety profiles. With a commitment to innovation and scientific excellence, Crystalgenomics strives to improve patient outcomes and advance the field of drug discovery.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

10 Patents

#75 in Gyeonggi-do

#1,033 in South Korea

#54,324 in the World

Gyeonggi-do, South Korea

Crystalgenomics, Inc.

Forward Citations = 29

34 inventors:

Joong Myung Cho (9 out of 13 patents)

Seonggu Ro (6 out of 6 patents)

Yong Rae Hong (3 out of 3 patents)

4. Jeong Eun Na (3 out of 6 patents)

5. Im Sook Min (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…